Felix Chu

发表

Ubiquitin ligase COP1 coordinates transcriptional programs that control cell type specification in the developing mouse brain

S. Kummerfeld, Rohit Reja, S. Sa, 2018, Proceedings of the National Academy of Sciences.

Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway

K. Yamaguchi, D. J. Matthews, F. Yakes, 2014, Molecular Cancer Therapeutics.

Abstract B269: Pharmacodynamic and correlative biomarker analyses in clinical trials of XL184, an oral, potent inhibitor of MET, VEGFR2, and RET

J. Li, Lora Zhao, V. Vysotskaia, 2009 .

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

Yongchang Shi, Yu-Chien Chou, K. Yamaguchi, 2011, Molecular Cancer Therapeutics.

In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.

F. Yakes, A. Joly, Lora Zhao, 2013, Thyroid : official journal of the American Thyroid Association.

Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigens.

G. Cavet, J. Defalco, W. Robinson, 2017, Clinical immunology.

33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)

W. Robinson, A. Manning-Boğ, T. Serafini, 2018, Journal of Immunotherapy for Cancer.

The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models

K. Yamaguchi, D. J. Matthews, F. Yakes, 2015, Molecular Cancer Therapeutics.

89 POSTER Evaluation of peripheral blood cells and hair as surrogate tissues for clinical trial pharmacodynamic assessment of XL147 and XL765, inhibitors of the PI3K signaling pathway

A. Laird, A. Sillman, Felix Chu, 2008 .

A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2

G. Shapiro, A. Zhu, E. Heath, 2010, Clinical Cancer Research.

Inhibition of the T790M Gatekeeper Mutant of the Epidermal Growth Factor Receptor by EXEL-7647

F. Yakes, A. Joly, J. Martini, 2007, Clinical Cancer Research.

CD8+ T cell infiltration in breast and colon cancer: A histologic and statistical analysis

James Ziai, J. Eastham‐Anderson, H. Gilbert, 2018, PloS one.

Generation and characterization of a unique reagent that recognizes a panel of recombinant human monoclonal antibody therapeutics in the presence of endogenous human IgG

R. Kelley, C. Eigenbrot, V. Quarmby, 2013, mAbs.

33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)

W. Robinson, A. Manning-Boğ, T. Serafini, 2018, Journal of Immunotherapy for Cancer.

Immunohistochemical Detection of FLAG-Tagged Endogenous Proteins in Knock-In Mice

J. Webster, D. French, K. Newton, 2015, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Heterogeneity of cytotoxic T cell infiltration in breast and colorectal cancer

James Ziai, J. Eastham‐Anderson, H. Gilbert, 2015, Journal of Immunotherapy for Cancer.

Preclinical Development Cabozantinib ( XL 184 ) , a Novel MET and VEGFR 2 Inhibitor , Simultaneously Suppresses Metastasis , Angiogenesis , and Tumor Growth

K. Yamaguchi, J. Lesch, F. Yakes, 2011 .

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

K. Yamaguchi, F. Yakes, A. Joly, 2011, Molecular Cancer Therapeutics.